review
highlight
ten
hot
topic
current
antivir
research
new
nucleosid
deriv
ie
show
high
potenti
direct
antivir
hepat
c
viru
hcv
ii
cyclopropavir
pursu
treatment
human
cytomegaloviru
hcmv
infect
iii
northmethanocarbathymidin
nmct
nlock
conform
show
promis
activ
herpesvirus
iv
oral
bioavail
prodrug
cidofovir
broadspectrum
activ
dna
virus
includ
polyoma
adeno
herp
pox
v
favipiravir
primarili
pursu
treatment
influenza
viru
infect
also
inhibit
replic
rna
virus
particularli
rna
virus
arena
bunya
hanta
vi
newli
emerg
antiarenavir
compound
effect
less
toxic
ubiquit
use
ribavirin
vii
antipicornaviru
agent
clinic
develop
pleconaril
viii
natur
product
receiv
increas
attent
potenti
antivir
drug
ix
antivir
target
specif
cellular
kinas
pathway
ie
mitogen
extracellular
kinas
mek
show
activ
influenza
virus
x
two
structur
unrel
compound
ie
broadspectrum
activ
virtual
envelop
rna
dna
virus
search
new
antivir
proceed
unabatedli
previou
review
stori
antivir
drug
discoveri
review
variou
subject
person
involv
review
hope
first
new
seri
address
hot
topic
area
antivir
research
past
year
signific
progress
made
requir
due
attent
compound
cover
still
preclin
stage
compound
success
complet
phase
ii
iii
clinic
trial
progress
approv
alreadi
approv
subject
review
instead
articl
base
compound
pipelin
offer
attract
perspect
futur
antivir
drug
sens
present
survey
littl
arbitrari
select
topic
depend
least
part
prejudic
number
factor
least
acquaint
subject
import
impetu
initi
review
base
icar
abstract
issu
antivir
research
vol
cover
present
icar
intern
confer
antivir
research
held
sofia
bulgaria
may
unfortun
could
attend
confer
guid
certain
devot
went
abstract
issu
spot
number
interest
lead
would
like
reflect
present
articl
nucleosid
analogu
target
hepat
c
viru
hcv
rna
polymeras
ii
cyclopropavir
treatment
human
cytomegaloviru
hcmv
infect
iii
northmethanocarbathymidin
nmct
treatment
herp
simplex
viru
type
type
epsteinbarr
viru
ebv
kaposi
sarcomaassoci
herpesviru
kshv
infect
iv
cidofovir
treatment
broad
varieti
dna
viru
infect
v
favipiravir
treatment
influenza
viru
infect
variou
rna
viru
infect
vi
increas
number
compound
found
effect
arenavirus
vii
new
picornaviru
ie
rhinoviru
inhibitor
viii
natur
product
antivir
activ
aglycoristocetin
deriv
tricin
dimethoxyflavon
ix
mitogen
extracellular
kinas
mek
inhibitor
act
cellular
target
effect
influenza
virus
x
two
uniqu
set
compound
effect
virtual
envelop
dna
rna
virus
taken
togeth
compound
x
cover
major
viral
pathogen
polyoma
adeno
herp
pox
picorna
flavi
arena
myxo
bunya
retrovirus
particularli
hsv
hcmv
hemorrhag
fever
influenza
human
immunodefici
viru
hiv
fluorocytidin
fdc
could
consid
first
nucleosid
analogu
fig
found
inhibit
hepat
c
viru
hcv
replicon
cell
cultur
triphosph
inhibit
polymeras
introduct
methyl
group
posit
cmethylcytidin
fig
confer
similar
potenc
fdc
hcv
replicon
assay
although
cmethylcytidin
fig
demonstr
somewhat
lesser
activ
hcv
cmethylcytidin
prodrug
cmethylcytidin
ovalin
ester
valopicitabin
fig
develop
later
drop
phase
ii
clinic
trial
introduct
azido
group
fig
difluorocytidin
fluoroarabinocytidin
significantli
increas
potenc
hcv
replicon
system
ie
effect
concentr
ec
valu
nm
latter
two
compound
triisobutyr
ester
prodrug
cmethylcytidin
fig
longer
develop
inhibitor
hcv
accord
reddi
et
al
accord
reddi
et
al
fig
current
phase
iib
clinic
trial
diisobutyr
ester
prodrug
fig
combin
studi
current
standard
care
soc
hcv
infect
ie
combin
pegyl
ribavirin
demonstr
efficaci
genotyp
patient
therefor
repres
first
direct
act
antivir
show
pangenotyp
hcv
coverag
clinic
cmethylcytidin
potent
inhibitor
hcv
replic
hcv
replicon
system
effici
diastereoselect
synthesi
see
wang
et
al
activ
rna
polymeras
level
must
phosphoryl
success
di
triphosph
final
activ
metabolit
act
chain
termin
rna
polymeras
howev
addit
triphosph
triphosph
uridin
counterpart
cmethyluridin
fig
also
form
second
metabolit
also
potent
inhibitor
hsv
rna
polymeras
deamin
occur
monophosph
level
fig
inact
hcv
replicon
system
phosphoramid
prodrug
fig
activ
system
releas
monophosph
phosphoryl
intracellularli
diand
triphosph
uridin
homolog
renam
anoth
phosphoramid
prodrug
fig
prepar
prove
pangenotyp
inhibitor
hcv
replic
howev
lesser
activ
replicon
mutant
mutat
remain
fulli
suscept
insid
cell
convert
monophosph
sens
consid
prodrug
fact
mixtur
two
diastereoisom
rp
diastereom
sp
diastereom
latter
activ
inhibitor
hcv
rna
replic
replicon
system
current
evalu
phase
ii
clinic
trial
monophosph
phosphoramid
prodrug
prepar
fig
prove
highli
activ
genotyp
hcv
rna
replic
replicon
system
genotyp
infecti
viru
product
hcv
replicon
harbor
mutat
r
phenoxyphosphonylamino
propion
acid
isopropyl
ester
activ
isom
mixtur
two
diastereoisom
recent
cyclic
phosphat
prodrug
fig
describ
base
antipangenotyp
hcv
activ
ec
replicon
rang
also
includ
activ
mutat
abil
produc
high
intracellular
triphosph
level
vitro
vivo
synthet
access
singl
diastereom
select
develop
compound
current
phase
clinic
trial
support
continu
develop
clinic
candid
treatment
hcv
infect
neopentyl
methoxi
phosphorylamino
propano
arylphosphoramid
cmethyl
guanosin
ec
hcv
replicon
around
separ
diastereom
shown
similar
activ
replicon
assay
complet
investig
new
drug
ind
enabl
studi
progress
human
clinic
trial
treatment
chronic
hcv
infect
cyclopropavir
fig
view
structur
relat
acyclovir
ganciclovir
penciclovir
acycl
side
chain
latter
replac
methylenecyclopropan
antivir
properti
known
sinc
decad
cyclopropavir
proven
effect
herpesvirus
proven
particularli
effect
anim
model
cytomegaloviru
cmv
infect
includ
scidhu
scid
sever
combin
immunodefici
mous
model
hcmv
addit
cyclopropavir
also
found
effect
vitro
human
herpesviru
type
like
hcmv
current
avail
drug
treatment
hcmv
infect
ganciclovir
cidofovir
foscarnet
valganciclovir
valin
ester
ganciclovir
esterif
ganciclovir
lvalin
increas
oral
bioavail
previous
also
shown
acyclovir
valaciclovir
would
later
shown
valin
ester
deoxylcytidin
valtorcitabin
cmethylcytidin
valopicitabin
also
lvalin
ester
cyclopropavir
valcyclopropavir
fig
construct
mice
oral
bioavail
valcyclopropavir
hcmv
strain
cyclopropavir
compar
ganciclovir
cyclopropavir
display
ec
fiveto
tenfold
lower
ganciclovir
also
case
mutat
affect
cyclopropavir
ganciclovir
suscept
fact
purifi
phosphoryl
cyclopropavir
monophosph
extens
ganciclovir
phosphoryl
stereoselect
cyclopropavir
monophosph
convert
success
diphosph
triphosph
latter
activ
metabolit
interact
hcmv
dna
polymeras
singl
cellular
enzym
guanosin
monophosph
kinas
gmpk
monophosph
form
viral
encod
kinas
new
safe
antihcmv
drug
eagerli
await
fact
cyclopropavir
excel
activ
hcmv
combin
specif
phosphoryl
viral
enzym
would
seem
justifi
develop
compound
valin
ester
valcyclopropavir
eventu
phosphon
cyclic
phosphon
well
curiou
regard
phosphon
cyclic
phosphon
fig
equal
activ
hcmv
phosphon
cyclic
phosphon
activ
herpesviru
ebv
nmethanocarbathymidin
nmct
pseudosugar
rigidli
fix
northern
confor
fig
first
synthes
marquez
et
al
found
exhibit
potent
antivir
activ
corrobor
subsequ
studi
nmct
appear
phosphoryl
monoand
diphosph
hsvencod
thymidin
kinas
inhibit
viral
dna
polymeras
triphosph
metabolit
kinas
would
prefer
substrat
adopt
sugar
conform
wherea
cellular
dna
polymeras
almost
exclus
incorpor
triphosph
lock
n
conform
notwithstand
presenc
higher
triphosph
level
sconform
smct
r
de
clercq
antivir
activ
vaccinia
viru
first
shown
carbocycl
thymidin
fig
nmct
found
highli
effect
orthopoxviru
infect
vivo
mice
although
lung
nasal
brain
viru
reduct
achiev
vaccinia
viru
infect
strain
nearli
extent
cidofovir
vaccinia
viru
lack
gene
encod
function
deoxyuridin
triphosphatas
dutpas
catalyz
convers
dutp
dump
continu
replic
well
vitro
vivo
prove
hypersensit
inhibitori
effect
nmct
activ
spectrum
nmct
activ
also
herpesvirus
ebv
kshv
appar
nmct
inhibit
lytic
kshv
dna
synthesi
triphosph
metabolit
produc
kshvinfect
cell
express
viral
encod
thymidin
kinas
recent
greener
enantioselect
synthesi
nmct
report
new
mct
distinct
nmct
name
isomct
fig
describ
highaffin
substrat
thymidin
kinas
nmct
show
potent
antihiv
activ
human
osteosarcoma
ho
cell
modifi
contain
express
thymidin
kinas
possibl
antihiv
activ
isomct
may
mask
cytotox
nmct
repres
interest
conform
concept
therapeut
util
howev
remain
demonstr
present
therapeut
option
ebv
kshv
infect
infect
may
well
repres
uniqu
opportun
clinic
potenti
nmct
explor
hdp
prodrug
acycl
nucleosid
phosphon
cidofovir
cdv
repres
oral
version
cidofovir
reduc
nephro
toxic
activ
form
hdpcdv
cidofovir
fig
explain
principl
possess
activ
spectrum
similar
cidofovir
thu
encompass
dna
virus
herp
adeno
polyoma
poxvirus
indic
could
given
oral
bioavail
safer
nephro
toxic
profil
replac
cidofovir
futur
therapeut
regimen
dissemin
central
nervou
system
cn
hsv
infect
firm
chimerix
cmx
appear
superior
acyclovir
oral
administ
hdpcdv
fourto
eightfold
activ
molar
basi
intraperiton
administ
cidofovir
hcmv
infect
scidhu
mice
hdpcidofovir
exhibit
multiplelog
enhanc
antivir
activ
hcmv
hsv
replic
vitro
oral
treatment
hdpcdv
effect
parenter
cdv
treatment
murin
cmv
infect
long
await
oral
hdpcdv
improv
outcom
cmv
infect
congenit
model
cmv
infect
pregnant
guinea
pig
ether
lipid
ester
cidofovir
hdpcdv
much
potent
cidofovir
adenoviru
replic
vitro
hdpcdv
suppress
adenovirusinduc
mortal
immunosuppress
hamster
power
model
evalu
efficaci
antiadenoviru
agent
first
case
success
erad
dissemin
adenoviru
infect
recent
report
sever
immunosuppress
pediatr
stem
cell
transplant
recipi
line
earlier
observ
inhibitori
effect
cidofovir
murin
primat
polyomavirus
cidofovir
shown
inhibit
polyomaviru
bk
replic
human
renal
tubular
cell
either
lipid
ester
cidofor
hdpcdv
shown
inhibit
polyomaviru
bk
replic
vitro
log
fold
lower
concentr
cidofovir
prove
highli
effect
inhibit
polyomaviru
bk
replic
primari
human
renal
tubular
epitheli
cell
point
potenti
treatment
bk
viru
nephropathi
seen
kidney
transplant
recipi
jc
polyomaviru
infect
human
oligodendrocyt
lead
develop
progress
multifoc
leukoencephalopathi
shown
suppress
polyomaviru
jc
human
fetal
brain
svg
cell
cultur
svg
cell
line
deriv
primari
human
brain
cell
transfect
simian
viru
express
antigen
cell
recent
shown
inhibit
polyomaviru
jc
replic
human
brain
progenitorderiv
astrocyt
case
progress
multifoc
leukoencephalopathi
accompani
idiopath
lymphocytopenia
respond
success
treatment
alkoxyalkyl
ester
cidofovir
includ
hdpcdv
intens
pursu
inhibit
orthopoxviru
replic
first
proven
activ
vitro
vaccinia
viru
cowpox
vivo
activ
virus
demonstr
efficaci
demonstr
lethal
mousepox
model
base
lethal
aerosol
ectromelia
viru
infect
ancr
mice
improv
model
evalu
antipoxviru
therapi
base
use
mice
infect
mousepox
ectromelia
viru
prove
efficaci
ancr
mice
ectromelia
viru
infect
mice
serv
model
support
licensur
antiorthopoxviru
therapeut
base
anim
efficaci
rule
genet
similar
ectromelia
viru
variola
monkeypox
virus
lethal
mousepox
model
complet
protect
mortal
achiev
administr
delay
late
day
postinfect
singl
dose
mgkg
administ
day
postinfect
suffic
effect
mousepox
model
also
efficaci
treatment
monkeypox
viru
infect
statidefici
mice
highli
virul
express
ectromelia
viru
recombin
may
afford
highest
efficaci
combin
anoth
antivir
drug
preand
postexposur
prophylact
efficaci
also
demonstr
rabbit
infect
rabbitpox
viru
compar
cdv
would
advantag
could
administ
oral
wherea
cdv
need
administ
intraven
unlik
cdv
may
lead
nephrotox
favipiravir
fig
current
clinic
trial
japan
phase
iii
unit
state
phase
ii
treatment
influenza
viru
infect
mention
buy
et
al
vitro
vivo
activ
first
report
furuta
et
al
compound
show
potent
inhibitori
activ
influenza
b
c
virus
activ
picornaand
paramyxovirus
activ
whatsoev
dna
virus
structur
immedi
clear
mode
action
differ
ion
channel
inhibitor
amantadin
rimantadin
well
neuraminidas
inhibitor
zanamivir
oseltamivir
mechan
action
address
furuta
et
al
within
cell
would
convert
ribofuranosyl
monophosph
purin
adenin
hypoxanthineguanin
phosphoribosyl
transferas
two
phosphoryl
would
gener
triphosph
rtp
activ
metabolit
latter
inde
activ
metabolit
also
shown
cell
infect
highli
pathogen
influenza
viru
meanwhil
sidwel
et
al
shown
oral
administ
dosag
mgkg
twice
daili
prevent
death
due
lethal
avian
influenza
viru
infect
mice
vitro
favipiravir
prove
antivir
activ
influenza
viru
strain
resist
antivir
drug
oseltamivir
vivo
synergist
effect
obtain
favipiravir
combin
oseltamivir
influenza
infect
carboxamid
group
present
favipiravir
reminisc
carboxamid
present
ribavirin
carboxamid
group
also
present
two
compound
structur
relat
fig
compound
share
ribavirin
broadspectrum
activ
variou
rna
virus
thu
show
activ
footandmouth
diseas
viru
fmdv
administ
food
could
power
tool
control
footandmouth
diseas
pig
proven
efficaci
yellow
fever
viru
yfv
hamster
model
yfv
infect
also
activ
bovin
viral
diarrhea
viru
bvdv
anoth
flaviviru
could
consid
surrog
viru
hepat
c
viru
hcv
also
efficaci
yfv
hamster
model
although
dose
requir
efficaci
hamster
higher
requir
efficaci
yet
improv
diseas
paramet
yfvinfect
hamster
may
indic
potenti
util
treatment
yfv
infect
human
rodent
mice
hamster
oral
administ
also
effect
west
nile
viru
wnv
anoth
flaviviru
relat
yfv
whether
analogu
would
effect
two
mosquito
born
flavivirus
dengu
viru
japanes
enceph
viru
remain
intrigu
possibl
worth
explor
western
equin
enceph
viru
weev
alphaviru
belong
broad
famili
flavivirida
would
seem
respond
treatment
antivir
activ
spectrum
extend
arenavirus
junin
viru
junv
pichind
viru
tacarib
viru
machupoviru
macv
guanarito
viru
gtov
replic
cell
cultur
could
inhibit
previous
note
inhibitori
effect
influenza
viru
antiarenaviru
activ
could
revers
addit
purin
pyrimidin
nucleosid
also
prove
efficaci
pichind
viru
infect
hamster
even
treatment
begun
anim
fell
ill
day
anim
began
succumb
diseas
thu
treatment
late
stage
arenavir
hemorrhag
fever
could
consid
altern
option
ribavirin
would
seem
import
sever
arenaviru
infect
lassa
fever
human
besid
arenaviru
infect
bunyavirus
punta
toro
la
cross
rift
valley
fever
sandfli
fever
viru
also
proven
sensit
inhibit
vitro
punta
toro
viru
also
vivo
mice
hamster
hamster
infect
punta
toro
viru
efficaci
mice
effect
bunyavirida
hantavirus
dobrava
mapor
found
sensit
inhibitori
effect
mapor
viru
phylogenet
similar
and
viru
princip
caus
hantaviru
cardiopulmonari
syndrom
hcp
argentina
would
seem
mandatori
explor
efficaci
suitabl
hantaviru
model
hamster
andor
mice
conclus
intrigu
new
antivir
compound
explor
clinic
potenti
preventiontherapi
influenza
viru
infect
also
broad
activ
spectrum
rna
strand
virus
target
action
rnadepend
rna
polymeras
rna
virus
structureact
relationship
pharmacodynam
rel
relat
structur
analogu
sinc
mccormick
pioneer
paper
effect
therapi
lassa
fever
ribavirin
ribavirin
remain
antivir
drug
avail
treatment
arenaviru
infect
inhibitori
effect
ribavirin
arenavirus
might
least
partial
attribut
lethal
mutagenesi
recent
year
antiarenavir
drug
develop
receiv
increas
attent
one
new
antiarenavir
drug
candid
favipiravir
see
preced
section
tacarib
arenaviru
infect
model
employ
explor
antivir
potenti
novel
aristeromycin
analogu
new
imidazo
thiazol
carbohydr
deriv
found
inhibit
replic
argentin
hemorrhag
fever
viru
junin
small
interf
si
rna
target
conserv
rna
termini
lassa
fever
viru
offer
therapeut
potenti
wherea
antimicrobi
cation
peptid
found
activ
junv
well
lassa
fever
viru
restrict
bone
marrow
stromal
antigen
also
call
tetherin
besid
inhibit
releas
also
inhibit
egress
arenavirus
tetherin
could
thu
consid
innat
immun
strategi
suppress
arenaviru
replic
lassa
fever
viral
nucleoprotein
np
endow
sever
function
ie
exoribonucleas
cdomain
involv
suppress
interferon
induct
capbind
site
ndomain
protect
cap
cap
snatch
may
serv
potenti
target
chemotherapeut
intervent
one
fascin
target
novel
antiarenaviru
strategi
arenaviru
envelop
glycoprotein
complex
gpc
process
cellular
site
proteas
strictli
requir
product
infecti
progeni
celltocel
viru
propag
small
molecul
fig
recent
report
potent
inhibitor
vitro
cellbas
assay
correl
compound
potent
antivir
activ
lassa
fever
viru
cell
cultur
small
molecular
weight
inhibitor
target
arenavir
entri
particular
viral
glycoprotein
first
announc
chosen
drug
develop
fig
arenaviru
gp
synthes
singl
polypeptid
undergo
posttransl
process
yield
matur
virion
glycoprotein
involv
receptor
bind
wherea
similar
fusion
protein
envelop
virus
retrovirus
paramyxovirus
filovirus
seri
small
molecul
includ
fig
identifi
target
arenaviru
gp
small
molecul
entri
inhibitor
includ
interact
envelop
gpc
arenavirus
stabil
complex
phinduc
activ
membran
fusion
endosom
fig
inhibit
phinduc
dissoci
receptorbind
subunit
gpc
thu
stabil
gpc
phacidif
would
otherwis
initi
fusion
process
antivir
potenc
fig
lassa
viru
arenaviru
pseudotyp
within
rang
nm
sensit
dictat
segment
amino
acid
within
subunit
region
includ
carboxytermin
region
ectodomain
transmembran
domain
envelop
protein
small
molecul
arenaviru
inhibitor
compar
ribavirin
guinea
pig
model
lassa
viru
infect
found
increas
surviv
rate
control
ribavirin
remain
establish
compar
arenaviru
inhibitor
favipiravir
term
efficaci
safeti
whether
efficaci
extrapol
lassa
arenaviru
infect
junin
machupo
sabia
guanarito
although
picornavirus
encompass
number
import
human
pathogen
includ
enterovirus
polio
coxsacki
b
echo
rhinovirus
still
singl
antipicornaviru
agent
approv
clinic
use
yet
wealth
compound
shown
inhibit
picornavirus
includ
especi
coxsacki
b
viru
number
natur
product
see
section
promin
among
current
envisag
antipicornaviru
therapi
origin
winthrop
compound
disoxaril
deriv
engag
specif
bind
viral
capsid
pleconaril
fig
prototyp
class
compound
shown
inhibit
replic
variou
enteroand
rhinovirus
demonstr
tent
efficaci
potenti
lifethreaten
enteroviru
infect
reject
us
fda
treatment
common
cold
sever
doubleblind
placebocontrol
trial
pleconaril
infant
enteroviru
mening
adult
common
cold
conduct
pevear
et
al
show
efficaci
pleconaril
reduc
durat
sever
common
cold
symptom
administ
within
hr
symptom
onset
relat
viru
suscept
pleconaril
de
palma
et
al
review
mention
phase
ii
doubleblind
placebocontrol
trial
evalu
effect
pleconaril
nasal
spray
common
cold
symptom
asthma
exacerb
follow
rhinoviru
exposur
complet
result
trial
yet
divulg
pleconaril
meantim
found
shorten
cours
ill
compar
placebo
patient
enterovir
mening
benefit
appear
modest
adjust
confound
variabl
pleconaril
effect
viral
replic
common
variabl
immunodefici
cvid
patient
parechovirusassoci
medicin
research
review
doi
enteropathi
new
pleconaril
deriv
report
activ
pleconarilresist
coxsacki
b
viru
meanwhil
new
benzimidazol
deriv
synthes
found
activ
coxsacki
viru
small
interf
si
rna
shown
block
coxsacki
b
viru
replic
synergist
activ
coxsacki
viru
obtain
sirna
combin
solubl
coxsackievirusadenoviru
receptor
new
class
compound
structur
describ
recent
describ
inhibit
varieti
enterovirus
coxsacki
coxsacki
echoviru
low
micromolar
concentr
earlier
paper
date
demonstr
coxsacki
virusinduc
myocard
mice
inhibit
mycophenol
mofetil
interferon
induc
ampligen
poli
poli
c
u
three
antipicornaviru
agent
current
clinic
develop
pleconaril
fig
pleconaril
develop
oral
formul
treatment
rhinoviru
infect
highrisk
patient
chronic
lung
diseas
oral
phase
ii
trial
symptomat
human
rhinoviru
infect
asthmat
adult
scrutini
treatment
polioviru
infect
ec
valu
respect
human
rhinoviru
type
enteroviru
pleconaril
human
rhinoviru
type
polioviru
type
pleconaril
behav
capsid
binder
could
requir
combin
provid
addit
slightli
synergist
antivir
effect
review
recent
antivir
direct
human
rhinovirus
could
use
treat
common
cold
also
employ
therapeut
prophylact
prevent
asthma
chronic
obstruct
pulmonari
diseas
copd
exacerb
highrisk
patient
natur
compound
primarili
origin
plant
receiv
increas
attent
antivir
potenti
typic
exampl
constitu
ardisia
chimensi
caffeoylquin
acid
schefflera
heptaphylla
origin
southern
china
found
activ
particularli
coxsacki
viru
norsesquiterpenoid
isol
root
phyllanthu
emblica
show
activ
coxsacki
viru
triterpenoid
isol
heptaphylla
fig
accredit
broader
activ
coxsacki
influenza
respiratori
syncyti
viru
rsv
fig
main
isoflavonoid
isol
astragalu
membranaceu
also
show
activ
coxsacki
viru
vitro
would
improv
surviv
rate
mice
infect
coxsacki
viru
flavan
diogalloyltricetifavan
isol
leav
pithecellobium
clypearia
would
show
activ
array
virus
coxsacki
influenza
rsv
triterpenoid
mention
homoisoflavonoid
fig
show
activ
coxsacki
viru
echoviru
polioviru
flavon
dimethoxyflavon
tricin
isol
bamboo
sasa
albomarginata
found
effect
hcmv
ec
mean
stronger
antivir
activ
ganciclovir
tricin
also
accredit
antiinfluenza
viru
activ
increas
oral
bioavail
tricin
conjug
alanineglutam
acid
prodrug
tricin
tricinalanineglutam
acid
show
excel
oral
bioavail
upon
oral
administr
rat
isoflavon
genistein
fig
origin
isol
ferment
broth
pseudomona
sp
initi
describ
tyrosinespecif
protein
kinas
inhibitor
recent
genistein
shown
inhibit
arenaviru
infect
put
inhibit
arenaviru
entri
occur
cholesteroldepend
clathrinmedi
endocyt
mechan
raoulic
acid
fig
princip
ingredi
raoulia
australi
shown
inhibit
picornavirus
rhinoviru
rhinoviru
coxsacki
coxsacki
enteroviru
ec
valu
rang
lower
concentr
aforement
triterpenoid
flavan
show
antivir
activ
howev
raoulic
acid
show
activ
influenza
b
terameprocol
methyl
deriv
nordihydroguaiaret
acid
phenol
antioxid
extract
creosot
bush
larrea
trident
terameprocol
fig
found
inhibit
growth
poxvirus
cowpox
vaccinia
prevent
spread
viru
particl
cell
cell
nigericin
also
known
antibiot
helexin
c
azalomycin
antibiot
polyetherin
also
shown
inhibit
poxviru
replic
previous
report
inhibit
polioviru
influenza
viru
replic
aglycoristocetin
deriv
cyclobutenedion
carri
hydrophob
chain
methylen
bi
phenylen
fig
inhibit
influenza
b
viru
infect
probabl
interfer
viral
entri
process
type
compound
deriv
glycopeptid
antibiot
previous
shown
inhibit
replic
retroand
coronavirus
inhibitori
effect
also
attribut
interfer
viru
entri
brassinosteroid
fig
repres
natur
occur
polyhydroxi
steroid
plant
hormon
modul
growth
differenti
plant
cell
antivir
activ
well
document
brassinosteroid
particularli
activ
arenavirus
tacarib
pichind
junin
biyouyanagin
b
origin
obtain
hypericum
chinens
shown
activ
hiv
compound
possess
antiarenaviru
antihiv
properti
recent
obtain
total
synthesi
origin
assign
structur
revis
fig
conclus
wealth
natur
product
report
possess
antivir
properti
major
case
chemic
structur
well
identifi
full
antivir
activ
spectrum
compound
still
need
evalu
mode
action
elucid
importantli
therapeut
valu
delin
fig
prototyp
mek
mitogenactiv
proteinextracellular
signalregul
kinas
inhibitor
act
tier
serinethreonin
kinas
rafmekextracellular
regul
kinas
erk
signal
pathway
abl
suppress
propag
pandem
influenza
viru
highli
pathogen
avian
influenza
viru
vitro
vivo
among
mek
inhibitor
pd
pd
fig
use
clinic
trial
cancer
also
inhibitori
influenza
viru
infect
vitro
mek
inhibitor
reduc
viru
titer
vitro
vivo
also
reduc
proinflammatori
cytokin
express
mek
inhibitor
also
shown
suppress
influenza
b
viru
propag
importantli
date
happen
without
emerg
resist
viru
variant
demonstr
influenza
virus
easili
adapt
interfer
cellular
function
influenza
viru
infect
requir
induct
varieti
cytokin
includ
regul
transcript
factor
activ
famili
nk
junntermin
kinas
pathway
differ
protein
kinas
pathway
may
ultim
lead
rant
product
influenza
virusinfect
human
bronchial
epitheli
cell
rafmekerk
cascad
prototyp
mitogenactiv
protein
map
kinas
cascad
inhibit
rafsign
result
nuclear
retent
viral
ribonucleoprotein
complex
rnp
concomit
inhibit
viru
product
signal
mitogen
cascad
seem
essenti
influenza
viru
product
raf
mek
erk
pathway
play
import
role
replic
influenza
b
viru
also
replic
hiv
coxsacki
viru
coronaviru
hsv
mek
inhibitor
therefor
impair
propag
virus
specif
shown
rafmekerk
signal
cascad
activ
upon
infect
borna
diseas
viru
bdv
noncytolyt
highli
neurotrop
singlestrand
rna
viru
known
member
bornavirida
mononegaviral
mek
inhibitor
found
block
spread
bdv
cultur
cell
pathogenesi
hemorrhag
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
poorli
understood
hemorrhag
may
relat
induct
plasminogen
activ
inhibitor
type
via
activ
mekerk
pathway
mek
inhibitor
almost
complet
suppress
express
may
therefor
assum
suppress
hemorrhag
dhfdss
mekerk
pathway
also
associ
map
kinas
mapk
may
contribut
visna
virusinduc
process
lead
neurodegen
patholog
treatment
visna
virusinfect
cell
pd
fig
sinc
long
recogn
specif
inhibitor
mapk
abolish
visna
viru
replic
attest
potenti
pd
prevent
neuropatholog
visna
viru
replic
hcmv
depend
number
protein
kinas
pathway
sorafenib
multitarget
tyrosin
kinas
inhibitor
regist
anticanc
treatment
nexavar
r
bayer
onyx
pharmaceut
mapk
signal
pathway
sorafenib
may
also
interfer
replic
hcmv
imatinib
may
suppress
hcmv
replic
inactiv
plateletderiv
growth
receptor
pdgfr
critic
receptor
requir
hcmv
infect
variou
protein
kinas
inhibitor
contain
quinazolin
moieti
gefitinib
iressa
r
astrazeneca
teva
exert
antihcmv
activ
vitro
vivo
gefitinib
also
inhibit
hcmv
kinas
furthermor
hcmv
replic
depend
mekerk
pathway
could
therefor
suppress
mek
inhibitor
pd
conclus
mek
inhibitor
may
exhibit
broadspectrum
activ
multitud
virus
includ
influenza
herp
simplex
hiv
retrovirus
dengu
corona
hcmv
although
antivir
effect
could
consid
highli
specif
advantag
mek
inhibitor
view
action
target
cellular
process
unlik
lead
rapid
emerg
drug
resist
februari
issu
proc
natl
acad
sci
usa
appear
paper
broadspectrum
antivir
agent
target
entri
envelop
virus
follow
octob
issu
journal
remark
similar
antivir
activ
structur
unrel
inhibitor
rhodanin
deriv
rigid
amphipath
fusion
inhibitor
rafi
deriv
deoxyuridin
fig
possess
rigid
planar
hydrophob
moieti
hydrophob
moieti
would
intercal
lipid
bilay
viral
envelop
therebi
affect
viruscel
fusion
process
principl
activ
envelop
virus
two
import
human
pathogen
hcv
hsv
activ
demonstr
sever
other
ie
yellow
fever
dengu
japanes
enceph
fact
compound
compar
side
side
spectrum
activ
admittedli
easili
lead
drug
resist
develop
issu
address
vivo
activ
select
biodistribut
drug
formul
r
de
clercq
pharmacodynam
therapeut
valu
could
assess
herald
new
approach
strategi
combat
envelop
viru
infect
question
rais
whether
druggabl
well
author
thank
mr
christian
callebaut
profici
editori
assist
